NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP), today announces the appointment of Mark Gilbert, M.D., to its Board of Directors. Dr. Gilbert served as Chief Medical Officer of Juno Therapeutics prior to its acquisition by Celgene Corporation and currently serves as Executive Vice President of Research and Development at Acepodia. He succeeds outgoing Director Hoonmo Lee, who has stepped down from Indaptus’ Board as part of the transition, effective upon Dr. Gilbert’s appointment.
“We are delighted to have Dr. Gilbert join the Indaptus Board of Directors. His successful record of shepherding Juno’s novel CAR-T technology from bench to bedside brings valuable experience to the Indaptus Board. The Company looks forward to benefiting from his experience as we advance our new modality immunotherapy pipeline into and through the clinic,” said Jeffrey Meckler, Chief Executive Officer of Indaptus. “In addition, we thank Mr. Lee for his service to our Board and wish him well in his future endeavors.”
“I am excited to join the Indaptus Board of Directors, as I believe their novel, multi-TLR agonist therapeutic designed to safely prime and activate both the innate and adaptive immune systems has the potential to change oncology treatment paradigms and improve currently available immuno-oncology therapeutics. I look forward to bringing my experience advancing CAR-T therapies to bear with my fellow Directors and Senior Management as we guide Indaptus into the clinic and beyond,” said Dr. Gilbert.
Prior to joining Acepodia, Dr. Gilbert was Chief Medical Officer of Juno Therapeutics where he led the clinical development of some of the first CAR-T cell therapies. Before that, he held leadership positions at Bayer Schering Pharmaceuticals, Berlex Pharmaceuticals, Schering AG, and Immunex. Prior to his pharmaceutical industry positions, Dr. Gilbert was a faculty member at the Fred Hutchinson Cancer Research Center and the University of Washington, where he trained in the laboratory of Dr. Phil Greenberg, a scientific co-founder of Juno Therapeutics.
Dr. Gilbert received a B.S. in Biochemistry from the University of Iowa and an M.D. from the University of Iowa Medical School. He trained in internal medicine, infectious disease and medical oncology at the University of California, San Francisco, and the University of Washington, respectively.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity, including safe, durable anti-tumor response synergy with each of five different classes of existing agents, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy in preclinical models. Tumor eradication by Indaptus technology has demonstrated activation of both innate and adaptive immunological memory and, importantly, does not require provision of or targeting a tumor antigen in pre-clinical models. Indaptus has carried out successful GMP manufacturing of its lead clinical oncology candidate, Decoy20, and is currently completing other IND enabling studies.
